Biologics - such as monoclonal antibodies, vaccines, and cell and gene therapies -are rapidly transforming the healthcare landscape, particularly across the Asia-Pacific region. Their precision in treating chronic and complex diseases is fuelling unprecedented growth. The biologics market is expected to grow at a CAGR of 10.7% from 2025 to 2030. As more biologics advance from clinical development to commercialisation, the demand for high-quality, compliant raw materials - from cell culture media and excipients to packaging and processing components - continues to rise.
Meeting this demand requires more than innovation in science; it calls for robust supply chains, regulatory compliance, and strategic sourcing.
Understanding the Biologics Manufacturing Lifecycle
To meet the rising demand for biologics, manufacturers must carefully manage raw material needs across every phase of the product lifecycle. From cultivating cells to final packaging, each stage requires specific high-quality inputs that ensure the safety, efficacy and scalability of the final product
Upstream bioprocessing: The foundation of biologics
The manufacturing process begins with upstream bioprocessing, where living cells are cultured to produce the biologic’s active ingredients.
- Cell Culture Media: A critical component for growing cells that produce the biologic. These media contain essential salts, buffers, amino acids, and nutrients.
- Bioprocess aids, Reagents, and Solvents: Used for cell culture maintenance, purification, and analytical testing of biologics.
Downstream processing: Ensuring purity and consistency
Downstream processing plays a critical role in purifying the product and preparing it for the final formulation. Impurities are removed to ensure that stringent quality and regulatory standards are met.
- Filters and Resins: Key to downstream purification of biologics.
- Buffers and Media: Used in cell culture and microbial-derived biologics manufacturing processes.
Formulation: Enhancing stability
Stability and delivery begin with the right excipients. Excipients are added to ensure product stability, enhance efficacy, and extend shelf life. Common examples include diluents, stabilisers, preservatives, surfactants, and buffers, each selected to meet the specific needs of the biologic.
Fill, finish and packaging: Protecting product integrity
Biologics often require specialised primary packaging such as vials or pre-filled syringes, as well as compliant labels and secondary packaging for traceability and handling.
- Primary packaging: Includes sterile vials and pre-filled syringes, designed to maintain sterility and stability.
- Labels and Secondary Packaging: Compliant labelling and outer packaging are essential for identification, regulatory compliance, and safe handling across the supply chain.
Considerations when choosing raw materials
Biologic manufacturing is highly sensitive, and the choice of raw materials can directly affect product quality, safety, and regulatory approval.
Key considerations when selecting raw materials include:
- GMP Compliance: Materials must meet stringent GMP standards to ensure they are suitable for use in human therapeutics.
- Risk Assessment: Especially important for materials derived from animal sources or those used in cell and gene therapy, where viral safety and immunogenicity must be assessed.
- Supplier: Strong relationships with reliable suppliers are crucial for ensuring consistent quality and supply.
- Traceability: Maintaining a clear chain of custody and traceability for all raw materials is essential for regulatory compliance and product quality assurance.
As the biopharma industry advances, success hinges on the ability to scale innovation. This begins with sourcing the right raw materials. Whether it's cell culture media, formulation excipients, or GMP-grade packaging, every component plays a role in delivering safe and effective biologics.
At IMCD, we’re committed to supporting biopharma partners with high-quality, compliant, and innovative solutions tailored for biologics manufacturing. Together, we can drive the future of healthcare forward.